One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.
Fiche publication
Date publication
août 2017
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine, Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Gagniere C, Bouhnik Y,
Lien Pubmed
Résumé
We recently showed that vedolizumab is effective in patients with Crohn's disease (CD) and ulcerative colitis (UC) with prior anti-TNF failure in a multicentre compassionate early-access programme before marketing authorisation was granted to vedolizumab.
Mots clés
Adult, Antibodies, Monoclonal, Humanized, adverse effects, Cohort Studies, Colitis, Ulcerative, drug therapy, Crohn Disease, drug therapy, Female, Humans, Male, Middle Aged, Prospective Studies, Tumor Necrosis Factor-alpha, antagonists & inhibitors
Référence
Aliment. Pharmacol. Ther.. 2017 08;46(3):310-321